Skip Navigation



BJA Advance Access published online on June 10, 2005
British Journal of Anaesthesia, doi:10.1093/bja/aei158
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
95/2/247    most recent
aei158v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Benrath, J.
Right arrow Articles by Kress, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benrath, J.
Right arrow Articles by Kress, H. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Board of Management and Trustees of the British Journal of Anaesthesia 2005. All rights reserved. For Permissions, please e-mail: journal.permissions@oupjournals.org
Accepted April 25, 2005

Case Report

Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain

J. Benrath 1*, G. Scharbert 1, B. Gustorff 1, H.-A. Adams 2, and H. G. Kress 1

1 Department of Anaesthesiology and Intensive Care B, Medical University Vienna, Vienna, Austria
2 Department of Anaesthesia and Intensive Care, Medical University Hanover, Hanover, Germany

* To whom correspondence should be addressed.
J. Benrath, E-mail: justus.benrath{at}meduniwien.ac.at


  Abstract

Neuropathic pain sometimes needs invasive pain therapy. We present the case of a patient with cancer-related neuropathic pain untreatable with conventional pain therapy after tumour-embolization. The patient was treated successfully with intrathecal (i.t.) administration of S(+)-ketamine, in addition to morphine. Plasma concentrations of S(+)-ketamine were measured regularly throughout the treatment. Continuous i.t. administration of S(+)-ketamine over a period of 3 months demonstrated low plasma levels and no unwanted side-effects.

Keywords: anaesthetic administration, intrathecal; anaesthetic administration, long-term; anaesthetics i.v., S(+)-ketamine; pain, cancer-related; pain, neuropathic.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
J. Benrath, C. Brechtel, J. Stark, and J. Sandkuhler
Low dose of S(+)-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo
Br. J. Anaesth., October 1, 2005; 95(4): 518 - 523.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.